NCCN guidelines® insights bladder cancer, version 5.2018 featured updates to the NCCN guidelines

Thomas W. Flaig, Philippe E. Spiess, Neeraj Agarwal, Rick Bangs, Stephen A. Boorjian, Mark K. Buyyounouski, Tracy M. Downs, Jason A. Efstathiou, Terence Friedlander, Richard E. Greenberg, Khurshid A. Guru, Noah Hahn, Harry W. Herr, Christopher Hoimes, Brant A. Inman, Masahito Jimbo, A. Karim Kader, Subodh M. Lele, Joshua J. Meeks, Jeff Michalski & 16 others Jeffrey S. Montgomery, Lance C. Pagliaro, Sumanta K. Pal, Anthony Patterson, Daniel P. Petrylak, Elizabeth R. Plimack, Kamal S. Pohar, Michael P. Porter, Mark A. Preston, Wade J. Sexton, Arlene O. Siefker-Radtke, Jonathan Tward, Geoffrey Wile, Alyse Johnson-Chilla, Mary A. Dwyer, Lisa A. Gurski

Research output: Contribution to journalReview article

12 Citations (Scopus)

Abstract

The NCCN Clinical Practice Guidelines in Oncology for Bladder Cancer provide recommendations for the diagnosis, evaluation, treatment, and follow-up of patients with bladder cancer. These NCCN Guidelines Insights discuss important updates to the 2018 version of the guidelines, including implications of the 8th edition of the AJCC Cancer Staging Manual on treatment of muscle-invasive bladder cancer and incorporating newly approved immune checkpoint inhibitor therapies into treatment options for patients with locally advanced or metastatic disease.

Original languageEnglish (US)
Pages (from-to)1041-1053
Number of pages13
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume16
Issue number9
DOIs
StatePublished - Sep 1 2018

Fingerprint

Urinary Bladder Neoplasms
Guidelines
Neoplasm Staging
Therapeutics
Practice Guidelines
Muscles

All Science Journal Classification (ASJC) codes

  • Oncology

Cite this

Flaig, T. W., Spiess, P. E., Agarwal, N., Bangs, R., Boorjian, S. A., Buyyounouski, M. K., ... Gurski, L. A. (2018). NCCN guidelines® insights bladder cancer, version 5.2018 featured updates to the NCCN guidelines. JNCCN Journal of the National Comprehensive Cancer Network, 16(9), 1041-1053. https://doi.org/10.6004/jnccn.2018.0072

NCCN guidelines® insights bladder cancer, version 5.2018 featured updates to the NCCN guidelines. / Flaig, Thomas W.; Spiess, Philippe E.; Agarwal, Neeraj; Bangs, Rick; Boorjian, Stephen A.; Buyyounouski, Mark K.; Downs, Tracy M.; Efstathiou, Jason A.; Friedlander, Terence; Greenberg, Richard E.; Guru, Khurshid A.; Hahn, Noah; Herr, Harry W.; Hoimes, Christopher; Inman, Brant A.; Jimbo, Masahito; Kader, A. Karim; Lele, Subodh M.; Meeks, Joshua J.; Michalski, Jeff; Montgomery, Jeffrey S.; Pagliaro, Lance C.; Pal, Sumanta K.; Patterson, Anthony; Petrylak, Daniel P.; Plimack, Elizabeth R.; Pohar, Kamal S.; Porter, Michael P.; Preston, Mark A.; Sexton, Wade J.; Siefker-Radtke, Arlene O.; Tward, Jonathan; Wile, Geoffrey; Johnson-Chilla, Alyse; Dwyer, Mary A.; Gurski, Lisa A.

In: JNCCN Journal of the National Comprehensive Cancer Network, Vol. 16, No. 9, 01.09.2018, p. 1041-1053.

Research output: Contribution to journalReview article

Flaig, TW, Spiess, PE, Agarwal, N, Bangs, R, Boorjian, SA, Buyyounouski, MK, Downs, TM, Efstathiou, JA, Friedlander, T, Greenberg, RE, Guru, KA, Hahn, N, Herr, HW, Hoimes, C, Inman, BA, Jimbo, M, Kader, AK, Lele, SM, Meeks, JJ, Michalski, J, Montgomery, JS, Pagliaro, LC, Pal, SK, Patterson, A, Petrylak, DP, Plimack, ER, Pohar, KS, Porter, MP, Preston, MA, Sexton, WJ, Siefker-Radtke, AO, Tward, J, Wile, G, Johnson-Chilla, A, Dwyer, MA & Gurski, LA 2018, 'NCCN guidelines® insights bladder cancer, version 5.2018 featured updates to the NCCN guidelines', JNCCN Journal of the National Comprehensive Cancer Network, vol. 16, no. 9, pp. 1041-1053. https://doi.org/10.6004/jnccn.2018.0072
Flaig, Thomas W. ; Spiess, Philippe E. ; Agarwal, Neeraj ; Bangs, Rick ; Boorjian, Stephen A. ; Buyyounouski, Mark K. ; Downs, Tracy M. ; Efstathiou, Jason A. ; Friedlander, Terence ; Greenberg, Richard E. ; Guru, Khurshid A. ; Hahn, Noah ; Herr, Harry W. ; Hoimes, Christopher ; Inman, Brant A. ; Jimbo, Masahito ; Kader, A. Karim ; Lele, Subodh M. ; Meeks, Joshua J. ; Michalski, Jeff ; Montgomery, Jeffrey S. ; Pagliaro, Lance C. ; Pal, Sumanta K. ; Patterson, Anthony ; Petrylak, Daniel P. ; Plimack, Elizabeth R. ; Pohar, Kamal S. ; Porter, Michael P. ; Preston, Mark A. ; Sexton, Wade J. ; Siefker-Radtke, Arlene O. ; Tward, Jonathan ; Wile, Geoffrey ; Johnson-Chilla, Alyse ; Dwyer, Mary A. ; Gurski, Lisa A. / NCCN guidelines® insights bladder cancer, version 5.2018 featured updates to the NCCN guidelines. In: JNCCN Journal of the National Comprehensive Cancer Network. 2018 ; Vol. 16, No. 9. pp. 1041-1053.
@article{daab8651fc1e41eeb69f8e09345217b8,
title = "NCCN guidelines{\circledR} insights bladder cancer, version 5.2018 featured updates to the NCCN guidelines",
abstract = "The NCCN Clinical Practice Guidelines in Oncology for Bladder Cancer provide recommendations for the diagnosis, evaluation, treatment, and follow-up of patients with bladder cancer. These NCCN Guidelines Insights discuss important updates to the 2018 version of the guidelines, including implications of the 8th edition of the AJCC Cancer Staging Manual on treatment of muscle-invasive bladder cancer and incorporating newly approved immune checkpoint inhibitor therapies into treatment options for patients with locally advanced or metastatic disease.",
author = "Flaig, {Thomas W.} and Spiess, {Philippe E.} and Neeraj Agarwal and Rick Bangs and Boorjian, {Stephen A.} and Buyyounouski, {Mark K.} and Downs, {Tracy M.} and Efstathiou, {Jason A.} and Terence Friedlander and Greenberg, {Richard E.} and Guru, {Khurshid A.} and Noah Hahn and Herr, {Harry W.} and Christopher Hoimes and Inman, {Brant A.} and Masahito Jimbo and Kader, {A. Karim} and Lele, {Subodh M.} and Meeks, {Joshua J.} and Jeff Michalski and Montgomery, {Jeffrey S.} and Pagliaro, {Lance C.} and Pal, {Sumanta K.} and Anthony Patterson and Petrylak, {Daniel P.} and Plimack, {Elizabeth R.} and Pohar, {Kamal S.} and Porter, {Michael P.} and Preston, {Mark A.} and Sexton, {Wade J.} and Siefker-Radtke, {Arlene O.} and Jonathan Tward and Geoffrey Wile and Alyse Johnson-Chilla and Dwyer, {Mary A.} and Gurski, {Lisa A.}",
year = "2018",
month = "9",
day = "1",
doi = "10.6004/jnccn.2018.0072",
language = "English (US)",
volume = "16",
pages = "1041--1053",
journal = "Journal of the National Comprehensive Cancer Network : JNCCN",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "9",

}

TY - JOUR

T1 - NCCN guidelines® insights bladder cancer, version 5.2018 featured updates to the NCCN guidelines

AU - Flaig, Thomas W.

AU - Spiess, Philippe E.

AU - Agarwal, Neeraj

AU - Bangs, Rick

AU - Boorjian, Stephen A.

AU - Buyyounouski, Mark K.

AU - Downs, Tracy M.

AU - Efstathiou, Jason A.

AU - Friedlander, Terence

AU - Greenberg, Richard E.

AU - Guru, Khurshid A.

AU - Hahn, Noah

AU - Herr, Harry W.

AU - Hoimes, Christopher

AU - Inman, Brant A.

AU - Jimbo, Masahito

AU - Kader, A. Karim

AU - Lele, Subodh M.

AU - Meeks, Joshua J.

AU - Michalski, Jeff

AU - Montgomery, Jeffrey S.

AU - Pagliaro, Lance C.

AU - Pal, Sumanta K.

AU - Patterson, Anthony

AU - Petrylak, Daniel P.

AU - Plimack, Elizabeth R.

AU - Pohar, Kamal S.

AU - Porter, Michael P.

AU - Preston, Mark A.

AU - Sexton, Wade J.

AU - Siefker-Radtke, Arlene O.

AU - Tward, Jonathan

AU - Wile, Geoffrey

AU - Johnson-Chilla, Alyse

AU - Dwyer, Mary A.

AU - Gurski, Lisa A.

PY - 2018/9/1

Y1 - 2018/9/1

N2 - The NCCN Clinical Practice Guidelines in Oncology for Bladder Cancer provide recommendations for the diagnosis, evaluation, treatment, and follow-up of patients with bladder cancer. These NCCN Guidelines Insights discuss important updates to the 2018 version of the guidelines, including implications of the 8th edition of the AJCC Cancer Staging Manual on treatment of muscle-invasive bladder cancer and incorporating newly approved immune checkpoint inhibitor therapies into treatment options for patients with locally advanced or metastatic disease.

AB - The NCCN Clinical Practice Guidelines in Oncology for Bladder Cancer provide recommendations for the diagnosis, evaluation, treatment, and follow-up of patients with bladder cancer. These NCCN Guidelines Insights discuss important updates to the 2018 version of the guidelines, including implications of the 8th edition of the AJCC Cancer Staging Manual on treatment of muscle-invasive bladder cancer and incorporating newly approved immune checkpoint inhibitor therapies into treatment options for patients with locally advanced or metastatic disease.

UR - http://www.scopus.com/inward/record.url?scp=85053006866&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053006866&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2018.0072

DO - 10.6004/jnccn.2018.0072

M3 - Review article

VL - 16

SP - 1041

EP - 1053

JO - Journal of the National Comprehensive Cancer Network : JNCCN

JF - Journal of the National Comprehensive Cancer Network : JNCCN

SN - 1540-1405

IS - 9

ER -